News & Updates
Filter by Specialty:
Show Multimedia Only
Casirivimab-imdevimab combo may reduce hospitalization in mild-to-moderate COVID-19
29 Sep 2021
byRoshini Claire Anthony
Treatment with a combination of the recombinant human IgG1 monoclonal antibodies casirivimab and imdevimab reduced hospitalization rates in high-risk patients with mild-to-moderate COVID-19, according to results of a retrospective study.
Casirivimab-imdevimab combo may reduce hospitalization in mild-to-moderate COVID-19
29 Sep 2021
Romosozumab prevents new vertebral fractures in postmenopausal women with osteoporosis
29 Sep 2021
byJairia Dela Cruz
Twelve months of treatment with romosozumab produce marked reductions in new vertebral fractures, especially moderate-to-severe fractures, among postmenopausal women with osteoporosis, according to a study.
Romosozumab prevents new vertebral fractures in postmenopausal women with osteoporosis
29 Sep 2021
Add-on metoprolol of no benefit to high-risk prostate cancer patients
29 Sep 2021
Use of metoprolol among high-risk prostate cancer patients receiving androgen deprivation therapy does not appear to improve oncological outcomes, as shown in a study.
